Mabwell says China NMPA clears 9MW5211 vitiligo trial applicationPUBT·Jul 15 at 07:03 AM02493-0.66%688062-4.96%
Mabwell wins China NMPA IND clearance for LILRB4/CD3 bispecific 6MW5311 in blood cancersPUBT·Jun 23 at 07:00 PM688062-4.96%02493-0.66%
Mabwell Showcases Promising Nectin-4 ADC Data in Cervical Cancer at ESMO Gynae 2026Tip Ranks·Jun 18 at 09:43 AM688062-4.96%02493-0.66%
Mabwell's ESG rating upgraded to A, with a composite score of 7.28, leading the pharmaceutical industry rating同壁财经·Jun 3 at 05:40 AM688062-4.96%
23:30 ETMabwell Announces Latest Clinical Data on 9MW2821 to Be Presented at 2026 ASCO Annual Meeting as Oral and Poster Presentationsprnewswire·May 21 at 10:32 PM688062-4.96%02493-0.66%
Mabwell Wins Wider China Indications for Denosumab Biosimilar as Global Push AcceleratesTip Ranks·May 20 at 10:09 AM688062-4.96%02493-0.66%
20:00 ETWorld's First | Mabwell's 9MW5211 Receives FDA Clearance for Clinical Trial Applicationprnewswire·May 8 at 07:00 PM02493-0.66%688062-4.96%
